Year: 2026
Type: article
Abstract: Anorexia nervosa, a potentially fatal eating disorder, has few effective treatments. Researchers enrolled 21 adult women with the disorder in a pilot study involving three dosing sessions with COMP360, the proprietary synthetic psilocybin developed by Compass Pathways. The three sessions took place over 6 weeks in a fixed order: 1 mg, 25 mg, and 25 mg. Participants in the single-blind study also received talk therapy, and adverse events were monitored. The primary outcomes were measured by the Eating Disorder Examination (EDE) Interview and Readiness and Motivation Questionnaire (RMQ) precontemplation scores. The EDE was measured at the 6-week final visit, the 3-month follow-up, and the 6-month follow-up; the RMQ outcomes were scored at the 6-week final visit and compared between dosing days. At 12 months, the participants were followed up remotely. Relative to baseline, participants showed significant improvements in EDE scores and RMQ scores. The most common adverse events were headache, nausea, and dizziness; one participant made two suicide attempts within the 6–12-month follow-up period. The investigators concluded that their findings provide preliminary support for the feasibility, safety, and potential efficacy of psilocybin in treating adults with anorexia nervosa. Douglass, H. M., Spriggs, M. J., Godfrey, K., et al. (2026, Jul 8). Psilocybin therapy for adult females with anorexia nervosa: pilot study. Br J Psychiatry, 1–9. https://doi.org/10.1192/bjp.2026.10687 Online ahead of print.
DOI: 10.1002/pu.31522
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W7231913679
